Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENADE OL: Macitentan in HFpEF and PVD
NCT03714815Phase 2Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Dec 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of macitentan in heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease (PVD), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Number of Participants With All-cause Deaths, Number of Participants With All-cause Hospital Admissions and 11 more. Started Dec 2018; status: terminated.
02
Drugs
macitentan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)pulmonary vascular disease (PVD)
Beyond the preview
Go deeper on NCT03714815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03714815.